id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-274750-fynxciwg	Peterson, Danielle	Calm before the storm: understanding the role of JAK inhibitors in COVID-19	2020-04-25		.txt	text/plain	462	40	51	Based on these 51 considerations, we believe there is insufficient evidence to recommend continuing JAK inhibitors in 52 patients who are acutely infected with SARS-CoV-2. 53 54 Napolitano et al suggest that baricitinib and upadacitinib might be useful in treating the cytokine 55 release syndrome (CRS) that can occur in SARS-CoV-2 infection. Furthermore, there is 58 evidence in both rhesus macaques and mice infected with the original SARS virus, SARS-CoV, that a 59 suboptimal early anti-viral type I interferon response may predispose to this late manifestation. In summary, we believe there is insufficient evidence to recommend that JAK inhibitors be continued in 70 all patients taking these medications who are acutely infected with SARS-CoV-2. While JAK inhibitors 71 may prove useful in the treatment of SARS-CoV-2-associated CRS, this is a separate consideration of a 72 relatively uncommon manifestation of this viral infection that occurs late in disease course.	./cache/cord-274750-fynxciwg.txt	./txt/cord-274750-fynxciwg.txt